Eine offene, beobachtende Studie - Therapie des Morbus Parkinson mit retardiertem Levodopa/Carbidopa

Zusammenfassung

Retardiertes Levodopa/Carbidopa wird meist zur Vermeidung von nächtlichen Akinesen bei Patienten mit idiopathischem Morbus Parkinson abends eingesetzt. Ziel dieser offenen beobachtenden Studie mit 338 Parkinson-Patienten war, die Sicherheit, Verträglichkeit und Wirksamkeit während eines zwölfwöchigen Untersuchungszeitraumes zu dokumentieren. Die tägliche Dosis von retardiertem Levodopa/Carbidopa (Nacom® retard) wurde bis zum Ende der Studie entsprechend der Fachinformation auf 372 mg gesteigert. Darunter besserten sich signifikant Akinese, Rigor, Tremor, sowie Ausprägung von Dyskinesien und motorischen Fluktuationen. Die Verträglichkeit war gut, Nebenwirkungen traten nur bei zwei Patienten auf. Diese offene Studie zeigt, dass durch Erhöhung bzw. Titrierung des retardierten Levodopa-Präparats eine verbesserte Einstellung der Symptome nahezu ohne ernsthafte, die Lebensqualität beeinträchtigende Nebenwirkungen erreicht werden kann. Auch kann eine Verbesserung von Fluktuationen und Dyskinesien kurzfristig erzielt werden.

Summary

Sustained release levodopa/carbidopa formulations are mostly administered for the treatment for nocturnal akinetic episodes in patients with idiopathic Parkinson's disease (PD) in the evening. Objectives of this 12 week open observational trial on controlled release levodopa/carbidopa preparations (Nacom® retard) were, to demonstrate their safety, tolerability and efficacy in 338 previously treated PD patients. Daily dosage of sustained release levodopa/carbidopa was elevated to 372mg during the study interval. Akinesia, rigidity, tremor, intensity of fluctuations and dyskinesias significantly improved. The tolerability was good, only two adverse events appeared. This open observational trial shows, that elevation and/or titration of sustained release levodopa/carbidopa preparation induces reduction of PD symptoms and motor complications without additional appearance essentially quality of life reducing, concomitant side effects in the short-term.

Keywords:

parkinson - dopa - nacom - sinemet

Literatur

• 1 Cotzias GC, Duby S, Ginos JZ, Steck A, Papavasiliou PS. Dopamine analogues for studies of parkinsonism.  N Engl J Med. 1970;  283 1289
• 2 Wajsbort J, Dorner A, Wajsbort E. A comparative clinical investigation of the therapeutic effect of levodopa alone and in combination with a decarboxylase inhibitor (carbidopa) in cases of Parkinson's disease.  Curr Med Res Opin. 1978;  5 695-708
• 3 Müller T. Dopaminergic substitution in Parkinson's disease.  Expert Opin Pharmacother. 2002;  3 1393-403
• 4 Müller T, Benz S, Bornke C, Russ H, Przuntek H. Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease.  J Neural Transm. 2003;  110 603-9
• 5 Agid Y. Levodopa: is toxicity a myth?.  Neurology. 1998;  50 858-63
• 6 Agid Y, Chase T, Marsden D. Adverse reactions to levodopa: drug toxicity or progression of disease?.  Lancet. 1998;  351 851-2
• 7 Fahn S. Controversies in the therapy of Parkinson's disease.  Adv Neurol. 1996;  69 477-86
• 8 Fahn S. Is levodopa toxic?.  Neurology. 1996;  47 184-195
• 9 Lees AJ. L-dopa treatment and Parkinson's disease.  Q J Med. 1986;  59 535-47
• 10 Pfeiffer R. Optimization of levodopa therapy.  Neurology. 1992;  42 39-43
• 11 Quinn N. Drug treatment of Parkinson's disease.  BMJ. 1995;  310 575-9
• 12 Melamed E, Hefti F. Altered pharmacokinetics of L-dopa metabolism.  Neurology. 1985;  35 939-41
• 13 Murata M, Kanazawa I. Effects of chronic levodopa therapy on dopa pharmacokinetics.  Eur Neurol. 1997;  38 50-5
• 14 Robertson DR, Renwick AG, Wood ND, Cross N, Macklin BS, Fleming JS. et al. . The influence of levodopa on gastric emptying in man.  Br J Clin Pharmacol. 1990;  29 47-53
• 15 Yeh KC, August TF, Bush DF, Lasseter KC, Musson DG, Schwartz S. et al. . Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.  Neurology. 1989;  25-38
• 16 Gerlach M, Kuhn W, Müller T, Klotz P, Przuntek H. Sustained-release of levodopa: single dose study of a new formulation.  J Neural Transm Gen Sect. 1996;  103 717-27
• 17 Hardie RJ, Malcolm SL, Lees AJ, Stern GM, Allen JG. The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations.  Br J Clin Pharmacol. 1986;  22 429-36
• 18 Kurlan R, Nutt JG, Woodward WR, Rothfield K, Lichter D, Miller C. et al. . Duodenal and gastric delivery of levodopa in parkinsonism.  Ann Neurol. 1988;  23 589-95
• 19 Kurth MC. Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.  Drugs Aging. 1997;  10 332-40
• 20 Pappert EJ, Goetz CG, Niederman F, Ling ZD, Stebbins GT, Carvey PM. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation.  Neurology. 1996;  47 1493-5
• 21 Przuntek H, Welzel D, Gerlach M, Blumner E, Danielczyk W, Kaiser HJ. et al. . Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.  J Neural Transm Gen Sect. 1996;  103 699-715
• 22 Rascol O, Brooks DJ, Korczyn AD, De PP Deyn, Clarke CE, Lang AE. 056 Study Group . A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.  N Engl J Med. 2000;  342 1484-91
• 23 Poewe WH, Lees AJ, Stern GM. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.  Eur Neurol. 1987;  27 93-7
• 24 Rondot P, Ziegler M, Aymard N, Teinturier A. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.  Neurology. 1989;  39 74-7
• 25 Sage JI, Mark MH. Pharmacokinetics of continuous-release carbidopa/levodopa.  Clin Neuropharmacol. 1994;  17 1-6
• 26 Le Witt PA. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.  Neurology. 1992;  42 29-32
• 27 MacMahon DG, Sachdev D, Boddie HG, Ellis CJ, Kendal BR, Blackburn NA. A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease.  J Neurol Neurosurg Psychiatry. 1990;  53 220-3
• 28 Malcolm SL, Allen JG, Bird H, Quinn NP, Marion MH, Marsden CD. et al. . Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers.  Eur Neurol. 1987;  27 28-35
• 29 Stocchi F, Quinn NP, Barbato L, Patsalos PN, O'Connel MT, Ruggieri S. et al. . Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study.  Clin Neuropharmacol. 1994;  17 38-44
• 30 Scheife RT, Schumock GT, Burstein A, Gottwald MD, Luer MS. Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes.  Am J Health Syst Pharm. 2000;  57 953-62
• 31 Clarke CE. Medical management of Parkinson's disease.  J Neurol Neurosurg Psychiatry. 2002;  72 22-27
• 32 Maurel F, Lilliu H, Le Pen C. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].  Rev Neurol (Paris). 2001;  157 507-14
• 33 Singer E. Social costs of Parkinson's disease.  J Chronic Dis. 1973;  26 243-54
• 34 Stamm T, Spycher S, Engfer A, Fahrenkrug E. Krankheitskosten des Morbus Parkinson in Deutschland.  Psycho. 1996;  22 212-28
• 35 Cedarbaum JM, Kutt H, McDowell FH. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).  Neurology. 1989;  39 38-44
• 36 Manyam BV, Hare TA, Robbs R, Cubberley VB. Evaluation of equivalent efficacy of sinemet and sinemet CR in patients with Parkinson's disease applying levodopa dosage conversion formula.  Clin Neuropharmacol. 1999;  22 33-9
• 37 Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study.  The CR First Study Group. Eur Neurol. 1997;  37 23-7
• 38 Koller WC, Hutton JT, Tolosa E, Capilldeo R. Carbidopa/Levodopa Study Group. . Immediate-release and controlled-release carbidopa/levodopa in PD: a 5- year randomized multicenter study.  Neurology. 1999;  53 1012-9
• 39 Parkinson Study Group . Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.  JAMA. 2000;  284 1931-8
• 40 Przuntek H, Welzel D, Gerlach M, Blumner E, Danielczyk W, Kaiser HJ. et al. . Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.  J Neural Transm Gen Sect. 1996;  103 699-715
• 41 Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti JF Masso. et al. . Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial.  The PKDS009 Study Group. Drugs. 1998;  55 23-30
• 42 Cedarbaum JM, Breck L, Kutt H, Mc Dowell FH. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.  Neurology. 1987;  37 233-41
• 43 Chouza C, Aljanati R, Caamano JL, De Medina O, Scaramelli A, Buzo R. et al. . Long-term treatment with Madopar HBS in parkinsonians with fluctuations.  Adv Neurol. 1990;  53 519-26
• 44 Deleu D, Jacques M, Michotte Y, Ebinger G. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.  Neurology. 1989;  39 88-92
• 45 Jankovic J, Schwartz K, Vander LC. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations.  Mov Disord. 1989;  4 303-9
• 46 Pezzoli G, Tesei S, Ferrante C, Cossutta E, Zecchinelli A, Scarlato G. Madopar HBS in fluctuating parkinsonian patients: two-year treatment.  Mov Disord. 1988;  3 37-45

Korrespondenzadresse: